DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Ellis M, Coop A, Baljit S, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR. et al.
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
J Clin Oncol 2001; 19: 3808-3816
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.